Korean Market
PERI
Dongsung Pharmaceutical
★

Dongsung Pharmaceutical: Financial Structure Improved via Rehabilitation Plan and Capital Increase, Q1 Turns to Profit

 
MATR
Dongsung Pharmaceutical
★★

Dongsung Pharmaceutical Decides Capital Reduction Under Rehabilitation Plan, Delays Schedule

 
EXCH
Dongsung Pharmaceutical
★★

Management Dispute Resolved: Court Recommends Settlement, Directors Resign

 
EXCH
Dongsung Pharmaceutical
★★★

Dongsung Pharmaceutical Improvement Period Ends, Delisting Review Process Begins

 
MATR
Dongsung Pharmaceutical
★

Dongsung Pharmaceutical Decides to Cancel 250,000 Common Shares Under Rehabilitation Plan

 
EXCH
Dongsung Pharmaceutical
★

Decision to Appoint Audit Committee Members During Rehabilitation

 
EXCH
Dongsung Pharmaceutical
★★★★

Dong Sung Pharmaceutical Files to Terminate Rehabilitation: Normalization After 160 Billion Won Investment

 
PERI
Dongsung Pharmaceutical
★★★

Dongsung Pharm: 2025 operating loss of 10.1B KRW, rehabilitation plan approved with major shareholder change

 
PERI
Dongsung Pharmaceutical
★★★

Dongsung Pharm: Operating Loss, Qualified Opinion, Deteriorating Financial Health

 
PERI
Dongsung Pharmaceutical
★★★★

Dongsung Pharmaceutical Audit Report Corrected: Opinion Downgraded to Qualified, Internal Control Disclaimer

 
EXCH
Dongsung Pharmaceutical
★★★

Audit Report Correction: Prior Year Opinion Revised to Qualified, Internal Control Adverse

 
EXCH
Dongsung Pharmaceutical
★★★

Audit Report Correction: Qualified Opinion, Adverse Internal Control, Fraud Disclosure